Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

Invion Limited (IVX:AU) has announced Orphan Drug Designation Granted by U.S. FDA For Anal Cancer

Download the PDF here.

The Conversation (0)
Hanlim & Korean Government Fund Pathway to Clinical Trial

Hanlim & Korean Government Fund Pathway to Clinical Trial

Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
Invion Secures Expanded Photosoft Global Exclusive License

Invion Secures Expanded Photosoft Global Exclusive License

Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
Appendix 4C and Quarterly Activities Report - September 2025

Appendix 4C and Quarterly Activities Report - September 2025

Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
Funded Collaboration Agreement with Protect Animal Health

Funded Collaboration Agreement with Protect Animal Health

Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
Repayment of Lind Facility with Successful Capital Raise

Repayment of Lind Facility with Successful Capital Raise

Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
Lexaria Bioscience (NASDAQ:LEXX)

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's... Keep Reading...
Hand places a blue block labeled "M&A" atop a pyramid of wooden blocks with business icons.

Fit to Work: GLP-1 and Metabolic Health in the M&A Sector

Biotechnology, pharmaceutical and medtech companies each contributed about 30 percent of deal volume to overall mergers and acquisitions (M&A) activity in 2025.The surge is attributed to rising obesity and diabetes cases, with the 2025 World Obesity Atlas projecting that the total number of... Keep Reading...
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks in 2026

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the three best-performing Canadian biotech stocks... Keep Reading...

Interactive Chart

Latest Press Releases

Related News